Tumor Assessment Criteria in Phase I Trials: Beyond RECIST
- 20 January 2013
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (3), 395
- https://doi.org/10.1200/jco.2012.46.2184
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Change in Tumor Size by RECIST Correlates Linearly With Overall Survival in Phase I Oncology StudiesJournal of Clinical Oncology, 2012
- The use of tumor growth rate (TGR) in evaluating sorafenib and everolimus treatment in mRCC patients: An integrated analysis of the TARGET and RECORD phase III trials data.Journal of Clinical Oncology, 2012
- Tumour growth rates and RECIST criteria in early drug developmentEuropean Journal of Cancer, 2011
- Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit.Journal of Clinical Oncology, 2011
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase IIIJournal of Clinical Oncology, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007